Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
ESMO Gastrointestinal Oncology|February 6, 2026
An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinomaY Aoki, I Nakayama, Y Komura, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Safety and efficacy of perioperative FLOT regimen in Japanese patients with gastric, esophagogastric junction, or esophageal adenocarcinoma: a single-institution experienceS Takei, A Kawazoe, A Jubashi, et al.
ESMO Open|December 1, 2022
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancerE Van Cutsem, H Hochster, K Shitara, et al.
ESMO Open|December 12, 2025
E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I studyS Kondo, N Yamamoto, Y Katsuya, et al.
ESMO Open|August 9, 2021
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 studyE Van Cutsem, A Valderrama, Y-J Bang, et al.
ESMO Open|June 27, 2021
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS studyJ Tabernero, K Shitara, A Zaanan, et al.
British Journal of Cancer|November 28, 2013
Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancerK Shitara, S Yuki, D Tahahari, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ARCAD-Asia initiative: leveraging yesterday's data for tomorrowY Takeda, T Misumi, H Bando, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2018
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patientsK Shitara, T Yamanaka, T Denda, et al.
ESMO Open|August 15, 2024
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trialsF Lordick, E Van Cutsem, K Shitara, et al.
Pageof 8